USCOM (ASX:UCM) ROCE % : -47.71% (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is USCOM ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. USCOM's annualized ROCE % for the quarter that ended in Dec. 2023 was -47.71%.

USCOM ROCE % Historical Data

The historical data trend for USCOM's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

USCOM ROCE % Chart

USCOM Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-32.79

-28.99

-16.92

-32.41

-44.37

USCOM Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-28.91	-25.85	-42.20	-45.57	-47.71

USCOM ROCE % Calculation

USCOM's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-2.454	/	( ( (7.993 - 0.896)	+	(5.18 - 1.215) )	/ 2 )
	=	-2.454	/	( (7.097	+	3.965)	/ 2 )
	=	-2.454	/	5.531
	=	-44.37 %

USCOM's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-1.67	/	( ( (5.18 - 1.215)	+	(6.025 - 2.99) )	/ 2 )
	=	-1.67	/	( ( 3.965	+	3.035 )	/ 2 )
	=	-1.67	/	3.5
	=	-47.71 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

USCOM (ASX:UCM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

USCOM ROCE % Related Terms

Thank you for viewing the detailed overview of USCOM's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

USCOM (ASX:UCM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » USCOM Ltd (ASX:UCM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 8, 66 Clarence Street, Suite 2, Sydney, NSW, AUS, 2000

Website

https://www.uscom.com.au

USCOM Ltd is engaged in the development, design, manufacture, and marketing of premium non-invasive cardiovascular and pulmonary medical devices. The company's geographical segment includes Australia, Asia, America, Europe, and Other regions. It generates maximum revenue from Australia. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, SPIROSONIC, a pulmonary function testing device based on multi-path ultrasound technology and the VENTITEST and VENTITEST-S ultrasonic ventilator calibration devices for optimizing respiratory device performance.

USCOM (ASX:UCM) Headlines

No Headlines